These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38017389)

  • 1. TIGIT
    Tsakmaklis A; Farowski F; Zenner R; Lesker TR; Strowig T; Schlößer H; Lehmann J; von Bergwelt-Baildon M; Mauch C; Schlaak M; Knuever J; Schweinsberg V; Heinzerling LM; Vehreschild MJGT
    BMC Cancer; 2023 Nov; 23(1):1160. PubMed ID: 38017389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Microbiome in Advanced Melanoma: Where Are We Now?
    Fortman DD; Hurd D; Davar D
    Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
    Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
    BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma.
    Wind TT; Gacesa R; Vich Vila A; de Haan JJ; Jalving M; Weersma RK; Hospers GAP
    Melanoma Res; 2020 Jun; 30(3):235-246. PubMed ID: 31990790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT, a novel immune checkpoint therapy for melanoma.
    Tang W; Chen J; Ji T; Cong X
    Cell Death Dis; 2023 Jul; 14(7):466. PubMed ID: 37495610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
    Lee KA; Thomas AM; Bolte LA; Björk JR; de Ruijter LK; Armanini F; Asnicar F; Blanco-Miguez A; Board R; Calbet-Llopart N; Derosa L; Dhomen N; Brooks K; Harland M; Harries M; Leeming ER; Lorigan P; Manghi P; Marais R; Newton-Bishop J; Nezi L; Pinto F; Potrony M; Puig S; Serra-Bellver P; Shaw HM; Tamburini S; Valpione S; Vijay A; Waldron L; Zitvogel L; Zolfo M; de Vries EGE; Nathan P; Fehrmann RSN; Bataille V; Hospers GAP; Spector TD; Weersma RK; Segata N
    Nat Med; 2022 Mar; 28(3):535-544. PubMed ID: 35228751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
    Thompson NA; Stewart GD; Welsh SJ; Doherty GJ; Robinson MJ; Neville BA; Vervier K; Harris SR; Adams DJ; Dalchau K; Bruce D; Demiris N; Lawley TD; Corrie PG
    BMC Cancer; 2022 Jan; 22(1):99. PubMed ID: 35073853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
    Esen F; Deniz G; Aktas EC
    Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
    Patin EC; Dillon MT; Nenclares P; Grove L; Soliman H; Leslie I; Northcote D; Bozhanova G; Crespo-Rodriguez E; Baldock H; Whittock H; Baker G; Kyula J; Guevara J; Melcher AA; Harper J; Ghadially H; Smith S; Pedersen M; McLaughlin M; Harrington KJ
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors.
    Joachim L; Göttert S; Sax A; Steiger K; Neuhaus K; Heinrich P; Fan K; Orberg ET; Kleigrewe K; Ruland J; Bassermann F; Herr W; Posch C; Heidegger S; Poeck H
    EBioMedicine; 2023 Nov; 97():104834. PubMed ID: 37865045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
    Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
    Dravillas CE; Coleman SS; Hoyd R; Caryotakis G; Denko L; Chan CHF; Churchman ML; Denko N; Dodd RD; Eljilany I; Hardikar S; Husain M; Ikeguchi AP; Jin N; Ma Q; McCarter MD; Osman AEG; Robinson LA; Singer EA; Tinoco G; Ulrich CM; Zakharia Y; Spakowicz D; Tarhini AA; Tan AC;
    Cancer Res Commun; 2024 Aug; 4(8):1978-1990. PubMed ID: 39015091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood CD3+HLADR+ cells and associated gut microbiome species predict response and overall survival to immune checkpoint blockade.
    Gorgulho J; Roderburg C; Beier F; Bokemeyer C; Brümmendorf TH; Luedde T; Loosen SH
    Front Immunol; 2023; 14():1206953. PubMed ID: 37705980
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Bredon M; Danne C; Pham HP; Ruffié P; Bessede A; Rolhion N; Creusot L; Brot L; Alonso I; Langella P; Derosa L; Cortot AB; Routy B; Zitvogel L; Segata N; Sokol H
    Oncoimmunology; 2024; 13(1):2374954. PubMed ID: 38957477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma.
    Usyk M; Pandey A; Hayes RB; Moran U; Pavlick A; Osman I; Weber JS; Ahn J
    Genome Med; 2021 Oct; 13(1):160. PubMed ID: 34641962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota.
    Bouferraa Y; Fares C; Bou Zerdan M; Boyce Kennedy L
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Tonneau M; Nolin-Lapalme A; Kazandjian S; Auclin E; Panasci J; Benlaifaoui M; Ponce M; Al-Saleh A; Belkaid W; Naimi S; Mihalcioiu C; Watson I; Bouin M; Miller W; Hudson M; Wong MK; Pezo RC; Turcotte S; Bélanger K; Jamal R; Oster P; Velin D; Richard C; Messaoudene M; Elkrief A; Routy B
    Oncoimmunology; 2022; 11(1):2096535. PubMed ID: 35832043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.